Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect

Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect

  • May 6, 2026

The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse linked to improved outcomes in a pair of phase 2 trials last year.

Leave A Comment

Fields (*) Mark are Required